Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuromuscular Transmission

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Neuromuscular Transmission. Displaying page 1 of 1.
    EudraCT Number: 2017-000692-92 Sponsor Protocol Number: MK-8616-089 Start Date*: 2019-02-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade ...
    Medical condition: Reversal of neuromuscular blockade (NMB)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10018061 General anesthesia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) FI (Completed) BE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-003737-19 Sponsor Protocol Number: CHUB-ITF-sevo-propofol Start Date*: 2023-01-10
    Sponsor Name:CHU Brugmann
    Full Title: Influence of sevoflurane and propofol on maximum muscular strength, speed of contraction and relaxation, in humans: A pilot study.
    Medical condition: Impact of anesthetic drugs on neuromuscular transmission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000693-11 Sponsor Protocol Number: MK-8616-169 Start Date*: 2019-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade ...
    Medical condition: Neuromuscular Blockade reversal
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FI (Completed) HU (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002610-14 Sponsor Protocol Number: 79835 Start Date*: 2021-09-08
    Sponsor Name:Aarhus University Hospital, Department of Neurology
    Full Title: Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study.
    Medical condition: Post-COVID-19 Myopathy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10062913 Muscle weakness conditions HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000188-33 Sponsor Protocol Number: MK-8616-146 Start Date*: 2017-10-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003272-23 Sponsor Protocol Number: NUBE Start Date*: 2014-10-24
    Sponsor Name:Dr. Jordi Montero Homs- Unidad de Neuromuscular- Servicio de Neurología- Hospital Universitario de Bellvitge
    Full Title: Prospective Pilot Study of the treatment of compression of median nerve neuropathy with Nucleo CMP Forte®.
    Medical condition: Carpal Tunnel Syndrome (CTS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10052414 Unilateral carpal tunnel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005792-16 Sponsor Protocol Number: Rocuronium_HVR_OSAS Start Date*: 2012-02-10
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway pr...
    Medical condition: Obstuctive sleep apnea and acute hypoxic ventilatory response
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004423-36 Sponsor Protocol Number: MK-8616-104 Start Date*: 2015-01-12
    Sponsor Name:MSD Italia s.r.l.
    Full Title: Randomized, parallel group, controlled trial to compare two different “NMB + reversal” strategies in adult obese patients underwent laparoscopic abdominal surgery (Phase 4; Protocol No. MK-8616-104...
    Medical condition: Obese adults to be subjected to abdominal laparoscopic surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date*: 2005-05-19
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10028417 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001384-37 Sponsor Protocol Number: ECU-MG-303 Start Date*: 2020-10-07
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG)
    Medical condition: Refractory Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005619-35 Sponsor Protocol Number: REFINE2020 Start Date*: 2021-06-07
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-A...
    Medical condition: Generalized AChR-antibody positive Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005749-30 Sponsor Protocol Number: 2015-00887 Start Date*: 2016-06-23
    Sponsor Name:Karolinska Institutet
    Full Title: A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study
    Medical condition: New onset myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003898-59 Sponsor Protocol Number: EFC17262 Start Date*: 2021-11-12
    Sponsor Name:SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG)
    Medical condition: Myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2022-002301-24 Sponsor Protocol Number: NMD670-02-0001 Start Date*: Information not available in EudraCT
    Sponsor Name:NMD Pharma A/S
    Full Title: A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy
    Medical condition: Type 3 spinal muscular atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10079415 Spinal muscular atrophy type III LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Ongoing) DE (Ongoing) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002938-73 Sponsor Protocol Number: ARGX-113-1602 Start Date*: 2016-10-31
    Sponsor Name:Argenx BVBA
    Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness
    Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004085-19 Sponsor Protocol Number: ARGX-113-2001 Start Date*: 2021-02-24
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of ...
    Medical condition: Generalized Myasthenia Gravis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) BE (Ongoing) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000249-42 Sponsor Protocol Number: IMVT-1401-3101 Start Date*: 2022-10-12
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Genera...
    Medical condition: Generalized Myasthenia Gravis (gMG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA